
Andreas Struengmann & family
$11.12B
$244.7M (2.3%)
as of 05/20/25
About Andreas Struengmann & family
Andreas Struengmann and twin brother Thomas were early backers of BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.
The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.
The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
Personal stats
Citizenship
GermanySource of wealth
PharmaceuticalsResidence
Tegernsee, GermanyMarital status
MarriedBirth date
02/16/50 (age 75)Number of children
2Education
Medical Doctor, University at BuffaloSelf-made
self-madeAndreas Struengmann & family’s fortune is worth

185K
troy ounces of gold

171K
median U.S. household

111K
median U.S. income

0.222%
U.S. credit card volume

0.044%
GDP of the United States

0.033%
United States debt
Net worth history
Annual ranking
Did you know?
After studying medicine in Freiburg, Germany, Andreas worked as a doctor in South Africa.
Net worth over time
Real-time ranking
Financial assets
NASDAQ | BNTX-US
BioNTech Sponsored ADRundefined | undefined
FormyconImages © Forbes.com. All rights reserved.